Three new Cochrane reviews, commissioned by the World Health Organization, confirm that GLP‑1 medicines—including the well‑known Ozempic—can produce meaningful weight loss. The studies also flag serious concerns about the heavy involvement of drug makers in many of the trials.
The reviews examined three GLP‑1 receptor agonists. All three outperformed placebo in shedding pounds, yet the evidence gaps around long‑term safety, side‑effects and industry influence remain substantial.
From Diabetes Care to Obesity Treatment
GLP‑1 receptor agonists were originally created to help people with type‑2 diabetes manage blood sugar. Since their introduction in the mid‑2000s, they have lowered cardiovascular and kidney risks, aided modest weight loss, and reduced early mortality among diabetic patients.
More recently, researchers have repurposed these drugs for obesity. By mimicking a natural hormone that slows gastric emptying and boosts satiety, the medicines help people feel fuller longer. In the UK, they are approved for weight‑management when paired with a calorie‑controlled diet and regular exercise, either for obesity or for overweight individuals with weight‑related health problems.
How Much Weight Can Be Lost?
All three reviews reported consistent weight reductions over 12‑ to 24‑month periods, and the benefits seemed to persist while patients stayed on therapy.
- Tirzepatide (weekly injection) achieved an average drop of about 16 % of body weight after 12‑18 months. Data from eight randomized trials involving 6,361 participants suggest the effect could last up to 3.5 years, though safety information beyond that horizon is scarce.
- Semaglutide (also weekly) produced roughly an 11 % loss after 24‑68 weeks. Eighteen trials with 27,949 participants indicate the effect may endure for about two years. Users were more likely to lose at least 5 % of their weight but reported higher rates of mild‑to‑moderate gastrointestinal discomfort.
- Liraglutide (daily injection) showed a more modest 4‑5 % average reduction, based on 24 trials and 9,937 participants. Even so, more participants achieved clinically meaningful loss compared with placebo, though evidence beyond two years is limited.
When researchers looked at major cardiovascular events, overall quality of life, or mortality, the GLP‑1 drugs performed similarly to placebo. However, side‑effects—especially nausea and other digestive issues—were more common, leading some participants to stop treatment.
“These agents can deliver substantial weight loss, particularly in the first year,” says Juan Franco, co‑lead investigator at Heinrich Heine University Düsseldorf. “It feels like a breakthrough after decades of limited options for obesity.”
Industry Funding and Global Representation
A large share of the trials examined were funded and closely managed by the drug manufacturers themselves. Such involvement raises red flags about potential conflicts of interest and underscores the need for more independently funded research.
Most studies were carried out in middle‑ and high‑income nations; regions such as Africa, Central America and Southeast Asia were either sparsely represented or absent. Because diet, genetics and lifestyle differ worldwide, researchers stress the importance of testing these medicines across diverse populations.
“We need robust data on long‑term cardiovascular outcomes, especially in lower‑risk groups,” notes Eva Madrid, co‑lead researcher at Universidad de Valparaíso, Chile. “Weight regain after stopping therapy could blunt the benefits, so independent public‑health studies are essential.”
What Comes Next?
The reviews conclude that longer‑term, independently financed trials are vital for shaping clinical practice and public‑health policies. A clearer picture of sustained efficacy and safety will determine how GLP‑1 receptor agonists fit into the broader strategy for chronic weight management.
These WHO‑commissioned findings will feed directly into forthcoming global guidelines on the use of GLP‑1 drugs for obesity.